As of 2025-07-14, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (3.44) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.93 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -187.5%.
The range of the Relative Valuation is (3.15) - (3.90) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.2x - 25.4x | 23.0x |
| Forward P/E multiples | 15.0x - 22.6x | 16.9x |
| Fair Price | (3.15) - (3.90) | (3.44) |
| Upside | -180.1% - -199.3% | -187.5% |
| Date | P/E |
| 2025-07-11 | -22.78 |
| 2025-07-10 | -23.07 |
| 2025-07-09 | -23.13 |
| 2025-07-08 | -21.50 |
| 2025-07-07 | -21.04 |
| 2025-07-03 | -20.98 |
| 2025-07-02 | -21.04 |
| 2025-07-01 | -20.69 |
| 2025-06-30 | -21.10 |
| 2025-06-27 | -21.16 |
| 2025-06-26 | -21.68 |
| 2025-06-25 | -21.33 |
| 2025-06-24 | -21.27 |
| 2025-06-23 | -21.10 |
| 2025-06-20 | -21.33 |
| 2025-06-18 | -20.63 |
| 2025-06-17 | -20.29 |
| 2025-06-16 | -20.75 |
| 2025-06-13 | -20.63 |
| 2025-06-12 | -21.16 |
| 2025-06-11 | -20.69 |
| 2025-06-10 | -22.72 |
| 2025-06-09 | -22.20 |
| 2025-06-06 | -23.01 |
| 2025-06-05 | -21.39 |
| 2025-06-04 | -21.10 |
| 2025-06-03 | -19.82 |
| 2025-06-02 | -18.84 |
| 2025-05-30 | -17.56 |
| 2025-05-29 | -17.45 |
| 2025-05-28 | -16.69 |
| 2025-05-27 | -16.92 |
| 2025-05-23 | -16.58 |
| 2025-05-22 | -16.40 |
| 2025-05-21 | -16.29 |
| 2025-05-20 | -16.92 |
| 2025-05-19 | -16.23 |
| 2025-05-16 | -15.13 |
| 2025-05-15 | -14.72 |
| 2025-05-14 | -14.20 |
| 2025-05-13 | -14.37 |
| 2025-05-12 | -14.08 |
| 2025-05-09 | -14.78 |
| 2025-05-08 | -15.19 |
| 2025-05-07 | -14.26 |
| 2025-05-06 | -13.45 |
| 2025-05-05 | -13.56 |
| 2025-05-02 | -14.20 |
| 2025-05-01 | -13.85 |
| 2025-04-30 | -13.97 |